Use of off-label Vyvgart successful in case of hard-to-treat gMG
A woman with hard-to-treat generalized myasthenia gravis (gMG) who was seronegative, or tested negative for disease-driving self-directed antibodies, was successfully treated with off-label Vyvgart (efgartigimod alfa-fcab), as reported in a case study from Italy. According to researchers, this case provides evidence that limiting Vyvgart to MG patients with…